Company intelligence / Profile preview

Aurora Investment

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Completed Phase I/II trials with AU-101 in Sarcoma (Osteosarcoma) showing safety, tumor killing efficacy, and survival benefits; completed trial with AU-105 in Glioblastoma showing safety, ORR signals, and up to double historic survival; ongoing Phase I/II trials with AU-101 in Osteosarcoma and Recurrent Glioblastoma.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Aurora Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aurora Investment.

Explore the full profile